Fatty liver disease is projected to affect 1.8 billion people worldwide by 2050, driven by rising obesity and blood sugar levels, according to a new analysis published in The Lancet Gastroenterology & Hepatology.
The study, led by the Institute for Health Metrics and Evaluation at the University of Washington, analyzed health data from 1990 to 2023 across 204 countries using the Global Burden of Diseases framework. It found that cases of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, rose from 500 million in 1990 to 1.3 billion in 2023 — a 160 percent increase over three decades.
If current trends continue, MASLD will affect nearly one in four people globally by mid-century, with prevalence rates climbing from 14,429 to 18,615 cases per 100,000 inhabitants — a 29 percent rise. The primary drivers identified are increasing body mass index, elevated blood glucose, and tobacco use, particularly in populations undergoing rapid lifestyle and dietary shifts.
Men are disproportionately affected, with the highest concentration of cases occurring in males aged 35 to 39, even as women peak in the 55 to 59 age bracket. Regional hotspots include North Africa and the Middle East, where prevalence growth outpaces global averages. In the UK, rates jumped 33 percent — the steepest increase in Western Europe — followed by Australia at 30 percent and the US at 22 percent.
For more on this story, see Medical societies reclassify obesity as a chronic metabolic disease.
Despite the alarming trajectory, medical experts emphasize that liver fat is highly responsive to weight reduction. As noted in clinical guidance, when body weight decreases, liver fat content diminishes first among all fat deposits — offering a clear, measurable target for intervention.
This reversibility presents a narrow but critical window for public health action. Unlike visceral or subcutaneous fat, hepatic steatosis can improve rapidly with even modest weight loss, potentially preventing progression to inflammation, fibrosis, or cirrhosis. Though, the asymptomatic nature of early-stage MASLD means many remain undiagnosed until significant damage has occurred.
The divergence between the disease’s silent progression and its explosive growth underscores a systemic gap in screening and prevention. While treatment pathways exist, they rely on early detection — a challenge in healthcare systems where liver enzyme tests are not routine and symptoms only emerge in advanced stages.
Can fatty liver disease be reversed?
Yes, medical evidence shows that reducing body weight leads to a rapid decrease in liver fat, often before changes are seen in other fat stores. This makes the liver a highly responsive organ to lifestyle interventions such as improved diet and increased physical activity.
Why are more men affected by fatty liver disease at younger ages?
Data from the global analysis indicates that men aged 35 to 39 have the highest number of MASLD cases, likely due to a combination of higher visceral fat accumulation, lifestyle factors like diet and alcohol use, and lower rates of preventive healthcare engagement compared to women in the same age group.
